Related Experiment Video
Updated: Mar 27, 2026

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
Published on: April 19, 2024
Systemic Thrombolytic Resistance in Antithrombin III Deficiency Rescued by Catheter-Directed Thrombolysis: A Case
Byeng-Ju Son1, Sungyun Jung1, Byung-Jun Kim1
1Division of Cardiology, Department of Internal Medicine, Dongkang Medical Center, Ulsan, Republic of Korea.
Hereditary antithrombin III deficiency can make patients resistant to standard clot-busting drugs. Catheter-directed thrombolysis offers an effective alternative for severe deep-vein thrombosis when systemic therapy fails.
Area of Science:
- Cardiology
- Hematology
- Vascular Medicine
Background:
- Hereditary antithrombin III (AT III) deficiency is a rare thrombophilia.
- This condition can lead to resistance to systemic thrombolytic therapy.
- Massive iliofemoral deep-vein thrombosis (DVT) with high-risk pulmonary thromboembolism (PTE) is a critical condition.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care
Pulmonary Embolism III: Nursing Management

